• Citer

Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis

par Rescigno, Pasquale;Dolling, David;Conteduca, Vincenza;Rediti, Mattia ;Bianchini, Diletta;Lolli, Cristian;Ong, Michael;Li, Haoran;Omlin, Aurelius;Schmid, Sabine;Caffo, Orazio;Zivi, Andrea;Pezaro, Carmel C.J.;Morley, Courtney;Olmos, David;Romero-Laorden, Nuria;Castro, Elena;Saez, María Isabel;Mehra, Niven;Smeenk, Stella;Sideris, Spyridon ;Gil, Thierry ;Banks, Patricia;Sandhu, Shahneen S.K.;Sternberg, Cora Nanette;De Giorgi, Ugo;De Bono, Johann Sebastian
Référence European Urology Oncology
Publication Publié, 2019

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis
Auteur:	Rescigno, Pasquale; Dolling, David; Conteduca, Vincenza; Rediti, Mattia; Bianchini, Diletta; Lolli, Cristian; Ong, Michael; Li, Haoran; Omlin, Aurelius; Schmid, Sabine; Caffo, Orazio; Zivi, Andrea; Pezaro, Carmel C.J.; Morley, Courtney; Olmos, David; Romero-Laorden, Nuria; Castro, Elena; Saez, María Isabel; Mehra, Niven; Smeenk, Stella; Sideris, Spyridon; Gil, Thierry; Banks, Patricia; Sandhu, Shahneen S.K.; Sternberg, Cora Nanette; De Giorgi, Ugo; De Bono, Johann Sebastian
Informations sur la publication:	European Urology Oncology
Statut de publication:	Publié, 2019
Sujet CREF:	Généralités
Mots-clés:	Abiraterone acetate
	Enzalutamide
	Overall survival
	Prostate cancer
	Prostate-specific antigen
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:2588-9311
	info:doi/10.1016/j.euo.2019.06.008
	info:pii/S2588931119300835
	info:scp/85068675974